Comments
Specialty biopharmaceutical manufacturer, Celon Laboratories, has launched an alternative drug - Amphotericin B Emulsion, for the treatment of Mucormycosis, commonly known as Black Fungus.
Amphotericin B, is crucial to the treatment of Mucormycosis, of which a sudden resurgence is being witnessed off late among covid19 patients, across India.
Though Hyderabad-based Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany — lipoids. To bypass the bottleneck caused by this sourcing obstacle and increase production of this medication, Celon developed an alternative, an emulsion-based formulation.
Exhaustively developed by Celon’s in-house R & D team in a record three weeks, the emulsion-based formulation will provide leading hospitals and Covid-19 treatment centres with increased resources to treat the Black Fungus. Celon will manufacture 10,000 vials per day, which will ensure relief for approximately 6,000 patients monthly.
“The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. The company will start supplying the product the domestic market soon,’’ M. Nagesh Kumar, Managing Director, Celon Labs said in a release.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.